106 related articles for article (PubMed ID: 28108506)
1. Biomarker Dynamics in B-cell Lymphoma: A Longitudinal Prospective Study of Plasma Samples Up to 25 Years before Diagnosis.
Späth F; Wibom C; Krop EJ; Johansson AS; Bergdahl IA; Vermeulen R; Melin B
Cancer Res; 2017 Mar; 77(6):1408-1415. PubMed ID: 28108506
[TBL] [Abstract][Full Text] [Related]
2. Soluble B-cell activation marker of sCD27 and sCD30 and future risk of B-cell lymphomas: A nested case-control study and meta-analyses.
Hosnijeh FS; Portengen L; Späth F; Bergdahl IA; Melin B; Mattiello A; Masala G; Sacerdote C; Naccarati A; Krogh V; Tumino R; Chadeau-Hyam M; Vineis P; Vermeulen R
Int J Cancer; 2016 May; 138(10):2357-67. PubMed ID: 26684261
[TBL] [Abstract][Full Text] [Related]
3. Prediagnostic serum sCD27 and sCD30 in serial samples and risks of non-Hodgkin lymphoma subtypes.
Purdue MP; Lan Q; Langseth H; Grimsrud TK; Hildesheim A; Rothman N
Int J Cancer; 2020 Jun; 146(12):3312-3319. PubMed ID: 31523805
[TBL] [Abstract][Full Text] [Related]
4. Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development.
Saberi Hosnijeh F; Kolijn PM; Casabonne D; Nieters A; Solans M; Naudin S; Ferrari P; Mckay JD; Weiderpass E; Perduca V; Besson C; Mancini FR; Masala G; Krogh V; Ricceri F; Huerta JM; Petrova D; Sala N; Trichopoulou A; Karakatsani A; La Vecchia C; Kaaks R; Canzian F; Aune D; Boeing H; Schulze MB; Perez-Cornago A; Langerak AW; van der Velden VHJ; Vermeulen R
Sci Rep; 2020 Aug; 10(1):13814. PubMed ID: 32796953
[TBL] [Abstract][Full Text] [Related]
5. Circulating immune markers and risks of non-Hodgkin lymphoma subtypes: A pooled analysis.
Rhee J; Birmann BM; De Roos AJ; Epstein MM; Martinez-Maza O; Breen EC; Magpantay LI; Levin LI; Visvanathan K; Hosgood HD; Rohan TE; Smoller SW; Bassig BA; Qi L; Shu XO; Koh WP; Zheng W; Yuan JM; Weinstein SJ; Albanes D; Lan Q; Rothman N; Purdue MP
Int J Cancer; 2023 Mar; 152(5):865-878. PubMed ID: 36151863
[TBL] [Abstract][Full Text] [Related]
6. Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women.
Hussain SK; Hessol NA; Levine AM; Breen EC; Anastos K; Cohen M; D'Souza G; Gustafson DR; Silver S; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):2084-93. PubMed ID: 24045923
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Changes in Immune Activation Serum Biomarkers Prior to Diagnosis and Risk of B-cell NHL Subtypes.
Levin LI; Ramirez CM; Liao EL; Guo H; Kim BK; Marrogi AJ; Magpantay LI; Breen EC; Martínez-Maza O
Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):233-241. PubMed ID: 36409490
[TBL] [Abstract][Full Text] [Related]
8. Cytokines in serum in relation to future non-Hodgkin lymphoma risk: evidence for associations by histologic subtype.
Edlefsen KL; Martínez-Maza O; Madeleine MM; Magpantay L; Mirick DK; Kopecky KJ; LaCroix AZ; De Roos AJ
Int J Cancer; 2014 Aug; 135(4):913-22. PubMed ID: 24488825
[TBL] [Abstract][Full Text] [Related]
9. Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma.
De Roos AJ; Mirick DK; Edlefsen KL; LaCroix AZ; Kopecky KJ; Madeleine MM; Magpantay L; Martínez-Maza O
Cancer Res; 2012 Sep; 72(18):4733-43. PubMed ID: 22846913
[TBL] [Abstract][Full Text] [Related]
10. Intraindividual Long-term Immune Marker Stability in Plasma Samples Collected in Median 9.4 Years Apart in 304 Adult Cancer-free Individuals.
Späth F; Wu WY; Krop EJM; Bergdahl IA; Wibom C; Vermeulen R
Cancer Epidemiol Biomarkers Prev; 2021 Nov; 30(11):2052-2058. PubMed ID: 34426415
[TBL] [Abstract][Full Text] [Related]
11. B-cell stimulatory cytokines and markers of immune activation are elevated several years prior to the diagnosis of systemic AIDS-associated non-Hodgkin B-cell lymphoma.
Breen EC; Hussain SK; Magpantay L; Jacobson LP; Detels R; Rabkin CS; Kaslow RA; Variakojis D; Bream JH; Rinaldo CR; Ambinder RF; Martinez-Maza O
Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1303-14. PubMed ID: 21527584
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Tsuyama N; Ennishi D; Yokoyama M; Baba S; Asaka R; Mishima Y; Terui Y; Hatake K; Takeuchi K
Oncotarget; 2017 May; 8(20):33487-33500. PubMed ID: 28380441
[TBL] [Abstract][Full Text] [Related]
13. Pre-diagnostic blood immune markers, incidence and progression of B-cell lymphoma and multiple myeloma: Univariate and functionally informed multivariate analyses.
Vermeulen R; Saberi Hosnijeh F; Bodinier B; Portengen L; Liquet B; Garrido-Manriquez J; Lokhorst H; Bergdahl IA; Kyrtopoulos SA; Johansson AS; Georgiadis P; Melin B; Palli D; Krogh V; Panico S; Sacerdote C; Tumino R; Vineis P; Castagné R; Chadeau-Hyam M; ; Botsivali M; Chatziioannou A; Valavanis I; Kleinjans JCS; de Kok TMCM; Keun HC; Athersuch TJ; Kelly R; Lenner P; Hallmans G; Stephanou EG; Myridakis A; Kogevinas M; Fazzo L; De Santis M; Comba P; Bendinelli B; Kiviranta H; Rantakokko P; Airaksinen R; Ruokojarvi P; Gilthorpe M; Fleming S; Fleming T; Tu YK; Lundh T; Chien KL; Chen WJ; Lee WC; Kate Hsiao C; Kuo PH; Hung H; Liao SF
Int J Cancer; 2018 Sep; 143(6):1335-1347. PubMed ID: 29667176
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma.
Breen EC; Fatahi S; Epeldegui M; Boscardin WJ; Detels R; Martínez-Maza O
Tumour Biol; 2006; 27(4):187-94. PubMed ID: 16651853
[TBL] [Abstract][Full Text] [Related]
15. Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification.
Bessell EM; Humber CE; O'Connor S; English JS; Perkins W; Dickinson PD; Patel AN
Br J Dermatol; 2012 Nov; 167(5):1118-23. PubMed ID: 22759204
[TBL] [Abstract][Full Text] [Related]
16. The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia.
Schwarzmeier JD; Shehata M; Hilgarth M; Marschitz I; Louda N; Hubmann R; Greil R
Leuk Lymphoma; 2002 Mar; 43(3):549-54. PubMed ID: 12002758
[TBL] [Abstract][Full Text] [Related]
17. [R.E.A.L. classification of non-Hodgkin lymphoma from the clinico-oncologic viewpoint].
Meusers P; Brittinger G
Praxis (Bern 1994); 1998 Jun; 87(23):793-800. PubMed ID: 9654985
[TBL] [Abstract][Full Text] [Related]
18. Markers of Immune Activation and Inflammation, and Non-Hodgkin Lymphoma: A Meta-Analysis of Prospective Studies.
Makgoeng SB; Bolanos RS; Jeon CY; Weiss RE; Arah OA; Breen EC; Martínez-Maza O; Hussain SK
JNCI Cancer Spectr; 2018 Dec; 2(4):pky082. PubMed ID: 30873511
[TBL] [Abstract][Full Text] [Related]
19. Circulating sCD27 and sCD30 in pre-diagnostic samples collected fifteen years apart and future non-Hodgkin lymphoma risk.
Purdue MP; Lan Q; Hoffman-Bolton J; Hildesheim A; Callahan CL; Strickland P; Visvanathan K; Rothman N
Int J Cancer; 2019 Apr; 144(8):1780-1785. PubMed ID: 30230539
[TBL] [Abstract][Full Text] [Related]
20. Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis.
Chadeau-Hyam M; Vermeulen RC; Hebels DG; Castagné R; Campanella G; Portengen L; Kelly RS; Bergdahl IA; Melin B; Hallmans G; Palli D; Krogh V; Tumino R; Sacerdote C; Panico S; de Kok TM; Smith MT; Kleinjans JC; Vineis P; Kyrtopoulos SA;
Ann Oncol; 2014 May; 25(5):1065-72. PubMed ID: 24558024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
